Loading…

Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

Osteoprotegerin (OPG) has been associated with increased risk and severity of atherosclerotic disease in the general population. Since ankylosing spondylitis (AS) is a chronic inflammatory disease associated with accelerated atherosclerosis, we aimed to assess whether OPG levels correlate with disea...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental rheumatology 2014-09, Vol.32 (5), p.640-646
Main Authors: Genre, Fernanda, López-Mejías, Raquel, Miranda-Filloy, José A, Ubilla, Begoña, Carnero-López, Beatriz, Palmou-Fontana, Natalia, Gómez-Acebo, Inés, Blanco, Ricardo, Rueda-Gotor, Javier, Pina, Trinitario, González-Juanatey, Carlos, Llorca, Javier, González-Gay, Miguel Á
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 646
container_issue 5
container_start_page 640
container_title Clinical and experimental rheumatology
container_volume 32
creator Genre, Fernanda
López-Mejías, Raquel
Miranda-Filloy, José A
Ubilla, Begoña
Carnero-López, Beatriz
Palmou-Fontana, Natalia
Gómez-Acebo, Inés
Blanco, Ricardo
Rueda-Gotor, Javier
Pina, Trinitario
González-Juanatey, Carlos
Llorca, Javier
González-Gay, Miguel Á
description Osteoprotegerin (OPG) has been associated with increased risk and severity of atherosclerotic disease in the general population. Since ankylosing spondylitis (AS) is a chronic inflammatory disease associated with accelerated atherosclerosis, we aimed to assess whether OPG levels correlate with disease activity, systemic inflammation, metabolic syndrome, adipokines and biomarkers of endothelial cell activation in patients with AS undergoing TNF-α antagonist therapy. We assessed OPG plasma concentration in 30 non-diabetic AS patients without cardiovascular disease undergoing TNF-α antagonist-infliximab therapy. OPG levels were measured immediately before and after an infliximab infusion. Correlations of OPG levels with disease activity, clinical characteristics, systemic inflammation, metabolic syndrome features, adipokines and biomarkers of endothelial activation were assessed. Changes in OPG concentration following an infusion of anti-TNF-α monoclonal antibody-infliximab were also analysed. We found a positive correlation between OPG levels and markers of disease activity such as BASDAI and VAS spinal pain (r=0.497, p=0.01; r=0.390; p=0.04, respectively). No differences in OPG levels according to specific clinical features of the disease were seen. An inverse correlation between OPG levels and total cholesterol and LDL-cholesterol was also found (r=-0.451; p=0.02 and r=-0.411; p=0.03, respectively). A correlation between OPG and asymmetric dimethylarginine, a biomarker of endothelial cell activation, was also disclosed (r=0.533; p=0.01). No correlation between OPG level and insulin resistance was observed. An infliximab infusion did not lead to a significant reduction in OPG levels. OPG shows a correlation with markers of disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1586103763</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1586103763</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-c74200951bdf87b92666daebf48f7ff6f33e01a4fc9221a90af541d0790207643</originalsourceid><addsrcrecordid>eNo1kE1OwzAUhLMA0VK4AvKSTST_JE6yRBUFJEQ3RWIXvcTPqcG1Q-yCchuuwEU4E0Etq1nM981iTpI5FRVPy1y-zJLzEF4p5TKXxVky4zmraJaLefK1DhF9P_iIHQ7GkdYPA1qIGMiniVuiTEAISKCN5sPEkYBTBJ3ycYvWgD0UEI13ZNKdd6ky0GA07YS-jdYH4zoSeu_UaE00gfQTjS4GsncKh87_9ZunVfrzPRkROu9MiGTaH6AfL5JTDTbg5TEXyfPqdrO8Tx_Xdw_Lm8e054zFtC0yTmmVs0bpsmgqLqVUgI3OSl1oLbUQSBlkuq04Z1BR0HnGFC0qymkhM7FIrg-70xfvewyx3pnQorXg0O9DzfJSMioKKSb06ojumx2quh_MDoax_n9V_AK7_Xhe</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1586103763</pqid></control><display><type>article</type><title>Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy</title><source>Freely Accessible Journals</source><creator>Genre, Fernanda ; López-Mejías, Raquel ; Miranda-Filloy, José A ; Ubilla, Begoña ; Carnero-López, Beatriz ; Palmou-Fontana, Natalia ; Gómez-Acebo, Inés ; Blanco, Ricardo ; Rueda-Gotor, Javier ; Pina, Trinitario ; González-Juanatey, Carlos ; Llorca, Javier ; González-Gay, Miguel Á</creator><creatorcontrib>Genre, Fernanda ; López-Mejías, Raquel ; Miranda-Filloy, José A ; Ubilla, Begoña ; Carnero-López, Beatriz ; Palmou-Fontana, Natalia ; Gómez-Acebo, Inés ; Blanco, Ricardo ; Rueda-Gotor, Javier ; Pina, Trinitario ; González-Juanatey, Carlos ; Llorca, Javier ; González-Gay, Miguel Á</creatorcontrib><description>Osteoprotegerin (OPG) has been associated with increased risk and severity of atherosclerotic disease in the general population. Since ankylosing spondylitis (AS) is a chronic inflammatory disease associated with accelerated atherosclerosis, we aimed to assess whether OPG levels correlate with disease activity, systemic inflammation, metabolic syndrome, adipokines and biomarkers of endothelial cell activation in patients with AS undergoing TNF-α antagonist therapy. We assessed OPG plasma concentration in 30 non-diabetic AS patients without cardiovascular disease undergoing TNF-α antagonist-infliximab therapy. OPG levels were measured immediately before and after an infliximab infusion. Correlations of OPG levels with disease activity, clinical characteristics, systemic inflammation, metabolic syndrome features, adipokines and biomarkers of endothelial activation were assessed. Changes in OPG concentration following an infusion of anti-TNF-α monoclonal antibody-infliximab were also analysed. We found a positive correlation between OPG levels and markers of disease activity such as BASDAI and VAS spinal pain (r=0.497, p=0.01; r=0.390; p=0.04, respectively). No differences in OPG levels according to specific clinical features of the disease were seen. An inverse correlation between OPG levels and total cholesterol and LDL-cholesterol was also found (r=-0.451; p=0.02 and r=-0.411; p=0.03, respectively). A correlation between OPG and asymmetric dimethylarginine, a biomarker of endothelial cell activation, was also disclosed (r=0.533; p=0.01). No correlation between OPG level and insulin resistance was observed. An infliximab infusion did not lead to a significant reduction in OPG levels. OPG shows a correlation with markers of disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.</description><identifier>ISSN: 0392-856X</identifier><identifier>PMID: 25190453</identifier><language>eng</language><publisher>Italy</publisher><subject>Adipokines - blood ; Adult ; Aged ; Anti-Inflammatory Agents - therapeutic use ; Antibodies, Monoclonal - therapeutic use ; Biomarkers - blood ; Endothelial Cells - drug effects ; Endothelial Cells - immunology ; Endothelial Cells - metabolism ; Female ; Humans ; Inflammation Mediators - blood ; Infliximab ; Male ; Middle Aged ; Osteoprotegerin - blood ; Severity of Illness Index ; Spondylitis, Ankylosing - blood ; Spondylitis, Ankylosing - diagnosis ; Spondylitis, Ankylosing - drug therapy ; Spondylitis, Ankylosing - immunology ; Treatment Outcome ; Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors</subject><ispartof>Clinical and experimental rheumatology, 2014-09, Vol.32 (5), p.640-646</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25190453$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Genre, Fernanda</creatorcontrib><creatorcontrib>López-Mejías, Raquel</creatorcontrib><creatorcontrib>Miranda-Filloy, José A</creatorcontrib><creatorcontrib>Ubilla, Begoña</creatorcontrib><creatorcontrib>Carnero-López, Beatriz</creatorcontrib><creatorcontrib>Palmou-Fontana, Natalia</creatorcontrib><creatorcontrib>Gómez-Acebo, Inés</creatorcontrib><creatorcontrib>Blanco, Ricardo</creatorcontrib><creatorcontrib>Rueda-Gotor, Javier</creatorcontrib><creatorcontrib>Pina, Trinitario</creatorcontrib><creatorcontrib>González-Juanatey, Carlos</creatorcontrib><creatorcontrib>Llorca, Javier</creatorcontrib><creatorcontrib>González-Gay, Miguel Á</creatorcontrib><title>Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy</title><title>Clinical and experimental rheumatology</title><addtitle>Clin Exp Rheumatol</addtitle><description>Osteoprotegerin (OPG) has been associated with increased risk and severity of atherosclerotic disease in the general population. Since ankylosing spondylitis (AS) is a chronic inflammatory disease associated with accelerated atherosclerosis, we aimed to assess whether OPG levels correlate with disease activity, systemic inflammation, metabolic syndrome, adipokines and biomarkers of endothelial cell activation in patients with AS undergoing TNF-α antagonist therapy. We assessed OPG plasma concentration in 30 non-diabetic AS patients without cardiovascular disease undergoing TNF-α antagonist-infliximab therapy. OPG levels were measured immediately before and after an infliximab infusion. Correlations of OPG levels with disease activity, clinical characteristics, systemic inflammation, metabolic syndrome features, adipokines and biomarkers of endothelial activation were assessed. Changes in OPG concentration following an infusion of anti-TNF-α monoclonal antibody-infliximab were also analysed. We found a positive correlation between OPG levels and markers of disease activity such as BASDAI and VAS spinal pain (r=0.497, p=0.01; r=0.390; p=0.04, respectively). No differences in OPG levels according to specific clinical features of the disease were seen. An inverse correlation between OPG levels and total cholesterol and LDL-cholesterol was also found (r=-0.451; p=0.02 and r=-0.411; p=0.03, respectively). A correlation between OPG and asymmetric dimethylarginine, a biomarker of endothelial cell activation, was also disclosed (r=0.533; p=0.01). No correlation between OPG level and insulin resistance was observed. An infliximab infusion did not lead to a significant reduction in OPG levels. OPG shows a correlation with markers of disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.</description><subject>Adipokines - blood</subject><subject>Adult</subject><subject>Aged</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Biomarkers - blood</subject><subject>Endothelial Cells - drug effects</subject><subject>Endothelial Cells - immunology</subject><subject>Endothelial Cells - metabolism</subject><subject>Female</subject><subject>Humans</subject><subject>Inflammation Mediators - blood</subject><subject>Infliximab</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Osteoprotegerin - blood</subject><subject>Severity of Illness Index</subject><subject>Spondylitis, Ankylosing - blood</subject><subject>Spondylitis, Ankylosing - diagnosis</subject><subject>Spondylitis, Ankylosing - drug therapy</subject><subject>Spondylitis, Ankylosing - immunology</subject><subject>Treatment Outcome</subject><subject>Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors</subject><issn>0392-856X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNo1kE1OwzAUhLMA0VK4AvKSTST_JE6yRBUFJEQ3RWIXvcTPqcG1Q-yCchuuwEU4E0Etq1nM981iTpI5FRVPy1y-zJLzEF4p5TKXxVky4zmraJaLefK1DhF9P_iIHQ7GkdYPA1qIGMiniVuiTEAISKCN5sPEkYBTBJ3ycYvWgD0UEI13ZNKdd6ky0GA07YS-jdYH4zoSeu_UaE00gfQTjS4GsncKh87_9ZunVfrzPRkROu9MiGTaH6AfL5JTDTbg5TEXyfPqdrO8Tx_Xdw_Lm8e054zFtC0yTmmVs0bpsmgqLqVUgI3OSl1oLbUQSBlkuq04Z1BR0HnGFC0qymkhM7FIrg-70xfvewyx3pnQorXg0O9DzfJSMioKKSb06ojumx2quh_MDoax_n9V_AK7_Xhe</recordid><startdate>20140901</startdate><enddate>20140901</enddate><creator>Genre, Fernanda</creator><creator>López-Mejías, Raquel</creator><creator>Miranda-Filloy, José A</creator><creator>Ubilla, Begoña</creator><creator>Carnero-López, Beatriz</creator><creator>Palmou-Fontana, Natalia</creator><creator>Gómez-Acebo, Inés</creator><creator>Blanco, Ricardo</creator><creator>Rueda-Gotor, Javier</creator><creator>Pina, Trinitario</creator><creator>González-Juanatey, Carlos</creator><creator>Llorca, Javier</creator><creator>González-Gay, Miguel Á</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20140901</creationdate><title>Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy</title><author>Genre, Fernanda ; López-Mejías, Raquel ; Miranda-Filloy, José A ; Ubilla, Begoña ; Carnero-López, Beatriz ; Palmou-Fontana, Natalia ; Gómez-Acebo, Inés ; Blanco, Ricardo ; Rueda-Gotor, Javier ; Pina, Trinitario ; González-Juanatey, Carlos ; Llorca, Javier ; González-Gay, Miguel Á</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-c74200951bdf87b92666daebf48f7ff6f33e01a4fc9221a90af541d0790207643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adipokines - blood</topic><topic>Adult</topic><topic>Aged</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Biomarkers - blood</topic><topic>Endothelial Cells - drug effects</topic><topic>Endothelial Cells - immunology</topic><topic>Endothelial Cells - metabolism</topic><topic>Female</topic><topic>Humans</topic><topic>Inflammation Mediators - blood</topic><topic>Infliximab</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Osteoprotegerin - blood</topic><topic>Severity of Illness Index</topic><topic>Spondylitis, Ankylosing - blood</topic><topic>Spondylitis, Ankylosing - diagnosis</topic><topic>Spondylitis, Ankylosing - drug therapy</topic><topic>Spondylitis, Ankylosing - immunology</topic><topic>Treatment Outcome</topic><topic>Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Genre, Fernanda</creatorcontrib><creatorcontrib>López-Mejías, Raquel</creatorcontrib><creatorcontrib>Miranda-Filloy, José A</creatorcontrib><creatorcontrib>Ubilla, Begoña</creatorcontrib><creatorcontrib>Carnero-López, Beatriz</creatorcontrib><creatorcontrib>Palmou-Fontana, Natalia</creatorcontrib><creatorcontrib>Gómez-Acebo, Inés</creatorcontrib><creatorcontrib>Blanco, Ricardo</creatorcontrib><creatorcontrib>Rueda-Gotor, Javier</creatorcontrib><creatorcontrib>Pina, Trinitario</creatorcontrib><creatorcontrib>González-Juanatey, Carlos</creatorcontrib><creatorcontrib>Llorca, Javier</creatorcontrib><creatorcontrib>González-Gay, Miguel Á</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Genre, Fernanda</au><au>López-Mejías, Raquel</au><au>Miranda-Filloy, José A</au><au>Ubilla, Begoña</au><au>Carnero-López, Beatriz</au><au>Palmou-Fontana, Natalia</au><au>Gómez-Acebo, Inés</au><au>Blanco, Ricardo</au><au>Rueda-Gotor, Javier</au><au>Pina, Trinitario</au><au>González-Juanatey, Carlos</au><au>Llorca, Javier</au><au>González-Gay, Miguel Á</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy</atitle><jtitle>Clinical and experimental rheumatology</jtitle><addtitle>Clin Exp Rheumatol</addtitle><date>2014-09-01</date><risdate>2014</risdate><volume>32</volume><issue>5</issue><spage>640</spage><epage>646</epage><pages>640-646</pages><issn>0392-856X</issn><abstract>Osteoprotegerin (OPG) has been associated with increased risk and severity of atherosclerotic disease in the general population. Since ankylosing spondylitis (AS) is a chronic inflammatory disease associated with accelerated atherosclerosis, we aimed to assess whether OPG levels correlate with disease activity, systemic inflammation, metabolic syndrome, adipokines and biomarkers of endothelial cell activation in patients with AS undergoing TNF-α antagonist therapy. We assessed OPG plasma concentration in 30 non-diabetic AS patients without cardiovascular disease undergoing TNF-α antagonist-infliximab therapy. OPG levels were measured immediately before and after an infliximab infusion. Correlations of OPG levels with disease activity, clinical characteristics, systemic inflammation, metabolic syndrome features, adipokines and biomarkers of endothelial activation were assessed. Changes in OPG concentration following an infusion of anti-TNF-α monoclonal antibody-infliximab were also analysed. We found a positive correlation between OPG levels and markers of disease activity such as BASDAI and VAS spinal pain (r=0.497, p=0.01; r=0.390; p=0.04, respectively). No differences in OPG levels according to specific clinical features of the disease were seen. An inverse correlation between OPG levels and total cholesterol and LDL-cholesterol was also found (r=-0.451; p=0.02 and r=-0.411; p=0.03, respectively). A correlation between OPG and asymmetric dimethylarginine, a biomarker of endothelial cell activation, was also disclosed (r=0.533; p=0.01). No correlation between OPG level and insulin resistance was observed. An infliximab infusion did not lead to a significant reduction in OPG levels. OPG shows a correlation with markers of disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.</abstract><cop>Italy</cop><pmid>25190453</pmid><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0392-856X
ispartof Clinical and experimental rheumatology, 2014-09, Vol.32 (5), p.640-646
issn 0392-856X
language eng
recordid cdi_proquest_miscellaneous_1586103763
source Freely Accessible Journals
subjects Adipokines - blood
Adult
Aged
Anti-Inflammatory Agents - therapeutic use
Antibodies, Monoclonal - therapeutic use
Biomarkers - blood
Endothelial Cells - drug effects
Endothelial Cells - immunology
Endothelial Cells - metabolism
Female
Humans
Inflammation Mediators - blood
Infliximab
Male
Middle Aged
Osteoprotegerin - blood
Severity of Illness Index
Spondylitis, Ankylosing - blood
Spondylitis, Ankylosing - diagnosis
Spondylitis, Ankylosing - drug therapy
Spondylitis, Ankylosing - immunology
Treatment Outcome
Tumor Necrosis Factor-alpha - antagonists & inhibitors
title Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T13%3A23%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Osteoprotegerin%20correlates%20with%20disease%20activity%20and%20endothelial%20activation%20in%20non-diabetic%20ankylosing%20spondylitis%20patients%20undergoing%20TNF-%CE%B1%20antagonist%20therapy&rft.jtitle=Clinical%20and%20experimental%20rheumatology&rft.au=Genre,%20Fernanda&rft.date=2014-09-01&rft.volume=32&rft.issue=5&rft.spage=640&rft.epage=646&rft.pages=640-646&rft.issn=0392-856X&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1586103763%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p211t-c74200951bdf87b92666daebf48f7ff6f33e01a4fc9221a90af541d0790207643%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1586103763&rft_id=info:pmid/25190453&rfr_iscdi=true